CD19 and neoplasm: We showed that while pharmacological ITK inhibition could mitigate T cell exhaustion and promote memory phenotype in CAR-T cells derived from patients with CLL, it only showed a trend but no significant increase of CLL-CD19-CAR-T cells in the tumor-bearing mouse model in vivo.